Keyphrases
Overall Survival
51%
Extranodal Marginal Zone Lymphoma
50%
Fludarabine
50%
Progression-free Survival
36%
Hazard Ratio
30%
Follicular Lymphoma
30%
Reduced-intensity Conditioning
30%
Allogeneic Transplantation
30%
Single Institution
27%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
27%
Intraocular Lymphoma
25%
Frontline Treatment
25%
Maintenance Rituximab
25%
Bendamustine-rituximab
25%
RASGRP2
25%
Mucosal Sites
25%
Extranodal Marginal Zone B-cell Lymphoma of mucosa-associated Lymphoid Tissue
25%
Chimeric Antigen Receptor T Cells (CAR-T)
25%
Non-Hodgkin Lymphoma
25%
T Cell Receptor
25%
Chimeric Antigen Receptor T-cell Therapy
25%
Acute Myeloid Leukemia
25%
Leukemia Patients
25%
Minimal Residual Disease
25%
Idarubicin
25%
Single-center Experience
25%
Granulocyte Colony-stimulating Factor (G-CSF)
25%
Cytarabine
25%
Radiation-based Method
25%
Melphalan
25%
Refractory AML
25%
Venetoclax
25%
Fludarabine-based Conditioning
25%
Splicing mutation
25%
Chronic Myeloid Leukemia
25%
Real-world Practice
25%
Relapsed or Refractory
25%
Myelodysplastic Syndrome
25%
Myeloablative Conditioning
25%
Stage I Disease
19%
International Prognostic Index
16%
Radiation Therapy
16%
Non-metropolitan
16%
Poverty Rate
16%
Lymphoma Patients
15%
MALT-IPI
15%
Spliceosome
15%
Relapse Risk
12%
Graft-versus-host Disease (GvHD)
12%
Non-relapse Mortality
12%
Medicine and Dentistry
MALT Lymphoma
100%
Progression Free Survival
81%
Radiation Therapy
66%
Overall Survival
66%
Fludarabine
50%
Mucosa-Associated Lymphoid Tissue
40%
Hazard Ratio
37%
Acute Myelogenous Leukemia
31%
Allograft
30%
Non Small Cell Lung Cancer
25%
Lymphocyte
25%
High Risk Population
25%
Cohort Analysis
25%
Lung Cancer
25%
Hemophagocytic Syndrome
25%
Nivolumab
25%
Neutrophil
25%
Patient with Non-Hodgkins Lymphoma
25%
Chimeric Antigen Receptor T-Cell Immunotherapy
25%
Granulocyte Colony Stimulating Factor
25%
Minimal Residual Disease
25%
Melphalan
25%
Cytarabine
25%
Idarubicin
25%
Reduced Intensity Conditioning
25%
Venetoclax
25%
Myeloablative Conditioning
25%
Acute Myeloid Leukemia
25%
Disease
22%
Immunotherapy
18%
Retrospective Study
16%
Biological Marker
12%
International Prognostic Index
12%
Oncology
12%
Disease Exacerbation
12%
Hemophagocytic Lymphohistiocytosis Syndrome
11%
Epstein Barr Virus
11%
Long Term Survival
10%
Infectious Complication
10%
Cumulative Incidence
9%
Monoclonal Gammopathy of Undetermined Significance
9%
Diseases
9%
B Cell
9%
Non-Relapse Mortality
8%
Logistic Regression Analysis
8%
Neoplasm
8%
Multivariate Analysis
8%
Central Nervous System
8%
Orbit Tumor
8%
Aggressive Lymphoma
8%
Pharmacology, Toxicology and Pharmaceutical Science
Overall Survival
51%
Fludarabine
50%
Progression Free Survival
43%
Bendamustine
25%
Nivolumab
25%
Non Small Cell Lung Cancer
25%
Lung Cancer
25%
Marginal Zone Lymphoma
25%
Follicular Lymphoma
25%
Rituximab
25%
T Lymphocyte Receptor
25%
Chimeric Antigen Receptor
25%
Nonhodgkin Lymphoma
25%
Granulocyte Colony Stimulating Factor
25%
Acute Myeloid Leukemia
25%
Idarubicin
25%
Minimal Residual Disease
25%
Melphalan
25%
Venetoclax
25%
Cytarabine
25%
Remission
19%
Immunotherapy
18%
Retrospective Study
16%
Chemotherapy
13%
Disease Exacerbation
12%
Biological Marker
12%
Long Term Survival
10%
Infectious Complication
10%
Adverse Event
9%
Diseases
9%
Disease
6%
Neoplasm
6%
Survival Rate
6%
Social Determinants of Health
6%
Clinical Feature
5%
Febrile Neutropenia
5%
Systemic Mycosis
5%
Cytopenia
5%
Bloodstream Infection
5%